Milgamma solution for injections 2 ml. ampoules №5

Description

Milgamma composition
In 2 milliliters of a solution intended for parenteral administration, the following active substances are contained: 100 mg of pyridoxine hydrochloride, 100 mg of thiamine hydrochloride, 100 mg of cyanocobalamin, as well as auxiliary ingredients: benzyl alcohol, sodium hydroxide, water for injection, lidocaine hydrochloride, sodium polyphosphate and potassium hexacyanoferrate tertiary.

Release form
It is made in ampoules of 2 milliliters in the form of a solution intended for intramuscular administration.

Pharmacological properties
Neurotropic B vitamins have a beneficial effect on inflammatory and degenerative diseases of the nerves and musculoskeletal system. They are used to eliminate deficient conditions, and in large doses they have analgesic properties, improve blood circulation and normalize the nervous system and hematopoiesis.

• Vitamin B1 is a very important active ingredient. In the body, vitamin B1 is phosphorylated with the formation of biologically active thiamine diphosphate (cocarboxylase) and thiamine triphosphate (TTP).
  Thiamine diphosphate as a coenzyme is involved in important functions of carbohydrate metabolism, which are crucial in the metabolic processes of nervous tissue, affect the conduction of nerve impulses at synapses. When vitamin B1 deficiency in the tissues is the accumulation of metabolites, primarily lactic and pyruvic acid, which leads to various pathological conditions and disorders of the nervous system.
• Vitamin B6 in its phosphorylated form (pyridoxal-5′-phosphate, PALP) is a coenzyme of a number of enzymes that interact in the overall non-oxidative metabolism of amino acids. Through decarboxylation they are involved in the formation of physiologically active amines (epinephrine, histamine, serotonin, dopamine, tyramine), through transamination – in anabolic and catabolic metabolic processes (eg, glutamate-oxaloacetatetransaminase, glutamate pyruvate-transamine also to various processes of amino acid cleavage and synthesis. Vitamin B6 acts on 4 different parts of tryptophan metabolism. Within the synthesis of hemoglobin, vitamin B6 catalyzes the formation of α-amino-b-ketoadinic acid.
• Vitamin B12 is required for cellular metabolism. It affects the function of hematopoiesis (external antianemic factor), participates in the formation of choline, methionine, creatinine, nucleic acids, has an analgesic effect.

Indications
Milgamma is intended for the treatment of neuralgias, neuritis, radicular syndrome, polyneuropathies of various origins, myalgias, retrobulbar neuritis, as well as paresis of the facial nerve. In addition, it can be used as part of the treatment of herpes zoster, as well as to eliminate the clinical manifestations of other herpes viral infections and as a general tonic.

Contraindications
Milgamma is not prescribed for patients suffering from severe chronic or acute heart failure at the stage of decompensation, impaired cardiac conduction.

Children
Accepted in pediatrics for children aged 16 years.

Application during pregnancy and lactation
Milgamma is not prescribed for women during pregnancy or in the lactation stage for the reason that there is no data on its effect on the fetus and the degree of penetration into the woman’s milk.

Method of administration and dosage
Treatment with Milgamma begins with intramuscular injection with 2 ml of the drug per day. Melgamma solution is injected deep into the / m. With maintenance therapy, the drug is administered in 2 ml doses two or three times every 7 days. If necessary, further treatment with the tablet form of the drug is possible: 1 tablet 1 time per day. Melgamma can be used to quickly relieve intense pain syndrome in parenteral or tablet form for this, the drug is prescribed 3 times a day, one tablet at a time. In the treatment of polyneuropathies, Melgamma is prescribed 1 tablet 3 times a day. The course of treatment with Melgamma does not exceed 1 month.

Overdose
In case of an overdose of the drug, an increase in symptoms characteristic of side effects is possible. In this case, symptomatic and syndromic therapy is prescribed.

Side effects
With individual intolerance or in the case of allergies, the development of:

• allergic reactions such as rash, pruritus, dyspnea, anaphylactic shock or Quincke’s edema;
• systemic reactions, manifested by increased sweating, arrhythmia or decreased heart rate, nausea, dizziness and convulsive syndrome.

Most often, systemic disorders occur when the dosage is exceeded or the drug is administered quickly.

Storage conditions and periods
It should be stored in a dark and dry place at a temperature not exceeding 15 ° C, not more than three years from the date of the drug release.